Literature DB >> 16430975

Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes.

Brian B Gowen1, Jeff Fairman, Donald F Smee, Min-Hui Wong, Kie-Hoon Jung, Anne M Pace, Matthew L Heiner, Kevin W Bailey, Steven W Dow, Robert W Sidwell.   

Abstract

Cationic liposome-DNA complexes (CLDC) have been demonstrated to induce potent antitumor activities. The ability of these complexes to elicit protective immunity against viral infections has not been fully explored. Here we report findings on the use of CLDC as an antiviral agent in a mouse model of acute phleboviral (Punta Toro virus) disease. CLDC treatment of mice challenged with Punta Toro virus (PTV) resulted in dramatic increases in survival and reduced viral burden and other parameters indicative of protection against disease. CLDC were effective when administered by intraperitoneal and intravenous routes and elicited protective immunity when given within 1 day of virus challenge. Treatments administered 36 h or longer after challenge, however, were not effective in preventing mortality or disease. CLDC treatment induced release of a number of potential antiviral cytokines including IFN-gamma, IL-12, and IFN-alpha. Taken together, our findings indicate that non-specific immunotherapy with CLDC appears to be an effective treatment for blocking PTV-induced disease and suggests that further exploration in other viral disease models may be warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16430975     DOI: 10.1016/j.antiviral.2005.12.002

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  18 in total

1.  Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge.

Authors:  Christopher H Logue; Aaron T Phillips; Eric C Mossel; Jeremy P Ledermann; Thomas Welte; Steve W Dow; Ken E Olson; Ann M Powers
Journal:  Antiviral Res       Date:  2010-05-07       Impact factor: 5.970

2.  Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.

Authors:  Katie L Propst; Ryan M Troyer; Lisa M Kellihan; Herbert P Schweizer; Steven W Dow
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

Review 3.  Liposome-nucleic acid immunotherapeutics.

Authors:  Steven Dow
Journal:  Expert Opin Drug Deliv       Date:  2008-01       Impact factor: 6.648

4.  A Lipid/DNA Adjuvant-Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge.

Authors:  Timothy D Carroll; Sinthujan Jegaskanda; Shannon R Matzinger; Linda Fritts; Michael B McChesney; Stephen J Kent; Jeffery Fairman; Christopher J Miller
Journal:  J Infect Dis       Date:  2018-08-14       Impact factor: 5.226

5.  Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens.

Authors:  Robin Ireland; Norma Olivares-Zavaleta; Jonathan M Warawa; Frank C Gherardini; Clayton Jarrett; B Joseph Hinnebusch; John T Belisle; Jeffery Fairman; Catharine M Bosio
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

6.  A novel vaccine adjuvant for recombinant flu antigens.

Authors:  Stella Chang; John Warner; Lily Liang; Jeff Fairman
Journal:  Biologicals       Date:  2009-03-12       Impact factor: 1.856

7.  Efficacy of cationic lipid-DNA complexes (CLDC) on hepatitis B virus in transgenic mice.

Authors:  John D Morrey; Neil E Motter; Brandon Taro; Marla Lay; Jeffery Fairman
Journal:  Antiviral Res       Date:  2008-02-25       Impact factor: 5.970

8.  Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis.

Authors:  Ryan M Troyer; Katie L Propst; Jeff Fairman; Catherine M Bosio; Steven W Dow
Journal:  Vaccine       Date:  2009-05-31       Impact factor: 3.641

9.  Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study.

Authors:  Jeff Fairman; Joseph Moore; Mathieu Lemieux; Koen Van Rompay; Yongzhi Geng; John Warner; Kristina Abel
Journal:  Hum Vaccin       Date:  2009-03-14

10.  Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models.

Authors:  Brian B Gowen; Min-Hui Wong; Kie-Hoon Jung; Donald F Smee; John D Morrey; Yousuke Furuta
Journal:  Antiviral Res       Date:  2009-10-27       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.